Immunome Valuation
| IMNM Stock | USD 9.82 0.40 4.25% |
At this time, the firm appears to be overvalued. Immunome retains a regular Real Value of $8.56 per share. The prevalent price of the firm is $9.82. Our model calculates the value of Immunome from evaluating the firm fundamentals such as Return On Asset of -0.4, shares outstanding of 62.42 M, and Return On Equity of -2.76 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Immunome's valuation include:
Price Book 2.7359 | Enterprise Value 375.5 M | Enterprise Value Ebitda (0.72) | Price Sales 60.5127 | Enterprise Value Revenue 34.6093 |
Overvalued
Today
Please note that Immunome's price fluctuation is slightly risky at this time. Calculation of the real value of Immunome is based on 3 months time horizon. Increasing Immunome's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Immunome stock is determined by what a typical buyer is willing to pay for full or partial control of Immunome. Since Immunome is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Immunome Stock. However, Immunome's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 9.82 | Real 8.56 | Target 8.0 | Hype 9.94 | Naive 7.63 |
The intrinsic value of Immunome's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Immunome's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Immunome helps investors to forecast how Immunome stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Immunome more accurately as focusing exclusively on Immunome's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Immunome's intrinsic value based on its ongoing forecasts of Immunome's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Immunome's closest peers.
Immunome Cash |
|
Immunome Valuation Trend
Knowing Immunome's actual value is paramount for traders when making sound investment determinations. Using both Immunome's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Immunome Total Value Analysis
Immunome is currently estimated to have valuation of 375.52 M with market capitalization of 612.93 M, debt of 1.65 M, and cash on hands of 34.65 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Immunome fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
375.52 M | 612.93 M | 1.65 M | 34.65 M |
Immunome Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Immunome has an asset utilization ratio of 9.44 percent. This suggests that the Company is making $0.0944 for each dollar of assets. An increasing asset utilization means that Immunome is more efficient with each dollar of assets it utilizes for everyday operations.Immunome Ownership Allocation
Immunome has a total of 62.42 Million outstanding shares. The majority of Immunome outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Immunome to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Immunome. Please pay attention to any change in the institutional holdings of Immunome as this could imply that something significant has changed or is about to change at the company. Also note that almost one hundred fourty-nine thousand eight hundred invesors are currently shorting Immunome expressing very little confidence in its future performance.Immunome Profitability Analysis
The company reported the previous year's revenue of 14.02 M. Net Loss for the year was (106.81 M) with profit before overhead, payroll, taxes, and interest of 0.About Immunome Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Immunome. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Immunome based exclusively on its fundamental and basic technical indicators. By analyzing Immunome's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Immunome's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Immunome. We calculate exposure to Immunome's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Immunome's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -8.9 M | -8.5 M | |
| Pretax Profit Margin | (6.86) | (7.20) | |
| Operating Profit Margin | (7.03) | (7.38) | |
| Net Loss | (6.86) | (7.20) | |
| Gross Profit Margin | (0.57) | (0.60) |
Immunome Growth Indicators
Investing in growth stocks can be very risky. If the company such as Immunome does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 19.8 M |
Immunome Current Valuation Indicators
Immunome's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Immunome's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Immunome, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Immunome's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Immunome's worth.When determining whether Immunome is a strong investment it is important to analyze Immunome's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Immunome's future performance. For an informed investment choice regarding Immunome Stock, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunome. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.